MWG Bets That Improved Software Will Give It Edge In Competitive Gene-Synthesis Market | GenomeWeb
As a growing number of companies jostle for position in the emerging market for gene-synthesis services, some are turning to software as a way to differentiate themselves from their competitors.
This week, MWG Biotech of Ebersberg, Germany, announced that it has developed a new software program for “optimizing” synthetic genes. The software, called GENEius and developed in collaboration with partner Eurofins Medigenomix, is primarily for internal use as part of MWG’s gene-synthesis service.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.